For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Visual guides › Pathway diagram

The growth-hormone axis, step by step

Where growth-hormone secretagogues actually act, and why 'the same dose as men' is an assumption, not a measurement.

Pathway diagram · 4 min read

Many popular peptides don't supply growth hormone, they nudge the body to release its own. To understand what they do and don't do, it helps to see the chain of command they plug into.

HypothalamusGHRH (+) · somatostatin (−)Pituitary glandreleases growth hormone (GH), in pulsesLiverGH stimulates IGF-1 productionTarget tissuesmuscle · bone · fat · connective tissueIGF-1 / GH negative feedbackGHRH analogsCJC-1295, tesamorelin,act via the GHRH receptorGhrelin mimetics (GHRPs)ipamorelin, acts via aseparate (ghrelin) receptorFOR WOMENFemale dosing for these islargely extrapolated from men.
The hypothalamic–pituitary axis that governs growth hormone. Secretagogues act near the top of the chain, through two different receptors. Feedback from IGF-1 and GH restrains the system.

Reading the chain

The hypothalamus sends two opposing signals: GHRH, which tells the pituitary to release growth hormone, and somatostatin, which tells it to hold back. The pituitary releases growth hormone (GH) in pulses. GH travels to the liver, which produces IGF-1, and both GH and IGF-1 act on muscle, bone, fat, and connective tissue. Rising IGF-1 and GH then feed back to quiet the hypothalamus and pituitary, a thermostat that keeps the system from running away.

Where the peptides act

  • GHRH analogs, CJC-1295 and tesamorelin imitate GHRH and act through the GHRH receptor.
  • Ghrelin mimetics (GHRPs), ipamorelin acts through a separate receptor (the ghrelin/GH-secretagogue receptor).

Because they act upstream and rely on the body's own pulsatile release and feedback, these compounds behave differently from injecting growth hormone directly, a distinction often flattened in marketing.

The female-evidence gap

Growth-hormone physiology is not sex-neutral: estrogen influences the GH/IGF-1 axis, and GH pulse patterns differ between women and men. Yet the dose figures circulating for these secretagogues are overwhelmingly derived from male subjects. On this site, the female-specific fields for these compounds are marked accordingly, most often as extrapolated or unstudied, because that is what the literature supports.

Estrogen modulates the growth-hormone axis, yet secretagogue dosing is largely derived from male data, so 'the same dose as men' is an assumption, not a measured finding.

Compounds referenced

IpamorelinC
Ipamorelin: of 49 PubMed records, 14 are tagged as including female subjects and 0 carry a sex-analysis tag.
CJC-1295 Without DACD
CJC-1295 Without DAC: of 5 PubMed records, 1 are tagged as including female subjects and 0 carry a sex-analysis tag.
TesamorelinA
Tesamorelin: of 103 PubMed records, 32 are tagged as including female subjects and 1 carry a sex-analysis tag.

Ready to take the next step?

Now that you've seen what the evidence does and doesn't say, find research-grade material from our verified supplier, or ask Vera for a sourced answer on any compound.

Shop research peptides ↗Ask VeraBrowse the database

Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Sources

  1. Endocrinology references on the hypothalamic–pituitary–GH/IGF-1 axis and its negative feedback.
  2. Literature on sex differences in GH pulsatility and estrogen's modulation of the GH/IGF-1 axis.
  3. Pharmacology of GHRH analogs (CJC-1295, tesamorelin) and ghrelin-receptor secretagogues (ipamorelin).

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe. Some outbound links are affiliate links.